The Medicine Maker

The creation and production of small molecules, biologics, and cutting-edge therapies rely on the skills, dedication, and expertise of a diverse group of professionals. At The Medicine Maker, we highlight these individuals, sharing success stories from the industry while also addressing its significant challenges. Our engaging content spans the full range of drug development, ensuring that everyone involved in medicine stays informed about the latest issues, trends, and innovations shaping the pharmaceutical sector. Additionally, The Medicine Maker team offers The Small Molecule Manufacturer, a platform dedicated to applauding the people, processes, and technologies that are revolutionizing the development and manufacturing of small molecule drugs.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1307279

United States

#598472

Health/Biotechnology and Pharmaceuticals

#574

Traffic sources

Monthly visitors

Articles

Kite, CAR Ts, and Access for Patients

4 days ago | themedicinemaker.com | Stephanie Vine

“Depending on the country, only about two in 10 eligible patients, on average, receive CAR T-cell therapy. These are potentially curative therapies, so a major area for us is realizing the full potential of CAR T and ensuring more patients have access. This means meeting patients where they are.
Interviews With Some of the Most Inspirational people in the Pharma Industry

4 days ago | themedicinemaker.com | Stephanie Vine

We’ve been publishing content for over a decade – and among my favourite features is our esteemed “Sitting Down With” interview series, which looks at the careers and achievements of outstanding individuals. Over the years, we’ve had the opportunity to speak to some incredible names and learn some amazing stories.
The Golden Ticket For GLP-1 Development

5 days ago | themedicinemaker.com | Stephanie Vine

The Golden Ticket program targets early-stage biotechs that “want to change the world,” with a focus on cardiometabolic health and rare blood and rare endocrine disorders. The prize includes rent-free space, mentoring and support from both Novo Nordisk and the Pioneer Group, and access to Pioneer’s venture programs. Entry closed in November 2024, with shortlisted companies invited to a pitching event. And the winner?
FUJIFILM Diosynth and Regeneron Sign 10-Year, $3 Billion Manufacturing Agreement

6 days ago | themedicinemaker.com | Stephanie Vine

FUJIFILM Diosynth Biotechnologies and Regeneron Pharmaceuticals have signed a 10-year manufacturing agreement valued at more than $3 billion. Under the agreement, FUJIFILM Diosynth will manufacture commercial and clinical biologics for Regeneron at its new facility in Holly Springs, North Carolina.
Going From Benchtop Chemist to CEO: Part 2

1 week ago | themedicinemaker.com | Stephanie Vine

Click here to read Part 1. In the late 90s, I was part of a major project team implementing a new ERP IT infrastructure. It was an exciting time – right before the year 2000. It was a significant investment and became a cornerstone of our future success. At that point, Colorcon was an international business, but hadn’t fully transitioned to a global structure. This IT project changed that, and our value proposition became clear because we had become a highly integrated organization.
From Benchtop Chemist to CEO

1 week ago | themedicinemaker.com | Stephanie Vine

I was born in the UK, where I studied at university and then started work with Colorcon in 1996. My first role within Colorcon was as a bench chemist, helping to develop new products to support the pharmaceutical industry. I approached my manager at the time about the possibility of transferring to the US – and fortunately, they were looking for technical expertise there so it was a very natural transition.
What Is Happening in US Life Sciences?

1 week ago | themedicinemaker.com | Rob Coker

As US president Donald Trump continues to impose his various agendas, we summarize the latest news and how it affects the manufacturing, distribution, and consumption of pharmaceuticals. Trump has initiated Section 232 investigations into pharmaceutical and semiconductor imports, citing national security concerns over US reliance on foreign production. Announced on April 14, analysts are preparing for 10-25 percent tariffs by mid-May.
Cell Therapy: Getting GMP Right

1 week ago | themedicinemaker.com | Stephanie Vine

Researchers from the Fred Hutchinson Cancer Center and Seidman Cancer Center have outlined foundational steps and quality considerations for establishing and maintaining GMP cell processing programs in academic and early-phase settings. The framework draws from international regulatory standards set by agencies such as the FDA, EMA, and ISO, and covers several areas, such as facility management, personnel, equipment management, supplier management, audits, among others.
Lore Gruenbaum on The Leukemia & Lymphoma Society, Blood Cancers, and Drug Development

1 week ago | themedicinemaker.com | Stephanie Vine

The Leukemia & Lymphoma Society (LLS) has been funding research since 1949 and has helped support several FDA-approved therapies, including Yescarta, Vyxeos, Elzonris, and Copiktra. In January 2025, Lore Gruenbaum became LLS’s Chief Scientific Officer. In part 1 of our interview with Gruenbaum, we learned about her career spanning big pharma and biotech. Here, we take a deep dive into the work of LLS, including success stories and the pressing research gaps that remain.
New Technologies in Precision Oncology

1 week ago | themedicinemaker.com | Rob Coker

Antibody-drug conjugates (ADCs) have long since promised to become the smart weapon of oncology by combining the specificity of antibodies with the potency of small molecule drugs. After decades of slow and steady progress, is the field finally hitting the accelerator? New advances in drug-to-antibody ratio (DAR), multispecific targeting, and nontraditional payloads could rewrite the ADC playbook, while simultaneously surfacing new scientific, manufacturing, and commercial challenges.